ClinVar Miner

Submissions for variant NM_000257.4(MYH7):c.1447G>A (p.Glu483Lys)

gnomAD frequency: 0.00001  dbSNP: rs121913651
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000539828 SCV000623642 pathogenic Hypertrophic cardiomyopathy 2024-01-20 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 483 of the MYH7 protein (p.Glu483Lys). This variant is present in population databases (rs121913651, gnomAD 0.002%). This missense change has been observed in individuals with hypertrophic cardiomyopathy (PMID: 10424815, 24111713, 27532257). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 14119). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYH7 protein function with a positive predictive value of 95%. This variant is found within a region of MYH7 between codons 181 and 937 that contains the majority of the myosin head domain. Missense variants in this region have been shown to be significantly overrepresented in individuals with hypertrophic cardiomyopathy (PMID: 27532257). For these reasons, this variant has been classified as Pathogenic.
Genetics and Genomics Program, Sidra Medicine RCV000539828 SCV001434145 uncertain significance Hypertrophic cardiomyopathy criteria provided, single submitter research
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001804733 SCV002050807 pathogenic Cardiomyopathy 2021-12-07 criteria provided, single submitter clinical testing Variant summary: MYH7 c.1447G>A (p.Glu483Lys) results in a conservative amino acid change located in the Myosin head, motor domain (IPR001609) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251460 control chromosomes (gnomAD). c.1447G>A has been reported in the literature in multiple individuals affected with Cardiomyopathy (examples: Richard_1999, Berge_2013 and Walsh_2017) . These data indicate that the variant is associated with disease. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Mendelics RCV002247341 SCV002517756 pathogenic MYH7-related skeletal myopathy 2022-05-04 criteria provided, single submitter clinical testing
National Institute of Allergy and Infectious Diseases - Centralized Sequencing Program, National Institutes of Health RCV000015176 SCV002522187 likely pathogenic Hypertrophic cardiomyopathy 1 2021-08-06 criteria provided, single submitter clinical testing
Ambry Genetics RCV002390109 SCV002700795 pathogenic Cardiovascular phenotype 2024-02-28 criteria provided, single submitter clinical testing The p.E483K pathogenic mutation (also known as c.1447G>A), located in coding exon 13 of the MYH7 gene, results from a G to A substitution at nucleotide position 1447. The glutamic acid at codon 483 is replaced by lysine, an amino acid with similar properties. This alteration is located in the myosin head domain, which contains a statistically significant clustering of pathogenic missense variants (Homburger JR et al. Proc Natl Acad Sci U S A, 2016 06;113:6701-6; Walsh R et al. Genet Med, 2017 02;19:192-203; Ambry internal data). This variant was detected in a family with hypertrophic cardiomyopathy (HCM) where it occurred alone in four affected individuals and co-occurred with an MYBPC3 alteration in two affected individuals with more significant hypertrophy (Richard P et al. J. Med. Genet., 1999 Jul;36:542-5). This variant has also been detected in multiple additional individuals from HCM cohorts (Berge KE et al. Clin. Genet., 2014 Oct;86:355-60; Lopes LR et al. Heart, 2015 Feb;101:294-301; Walsh R et al. Genet. Med., 2017 02;19:192-203; Stava TT et al. Eur J Prev Cardiol. 2022 Oct;29(13):1789-1799). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV001804733 SCV004239436 pathogenic Cardiomyopathy 2023-01-17 criteria provided, single submitter clinical testing
All of Us Research Program, National Institutes of Health RCV000539828 SCV004839123 likely pathogenic Hypertrophic cardiomyopathy 2024-01-08 criteria provided, single submitter clinical testing This missense variant replaces glutamic acid with lysine at codon 483 of the MYH7 protein. This variant is found within a highly conserved region of the myosin head domain. Computational prediction suggests that this variant may have a deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Missense variants in this region have been shown to be significantly overrepresented in individuals with hypertrophic cardiomyopathy (PMID: 27532257). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in at least six unrelated individuals affected with hypertrophic cardiomyopathy (PMID: 10424815, 12797239, 24111713, 24704860, 25351510, 27532257, 28378410, 33495596, 33495597). It has been shown that this variant segregates with disease in multiple individuals from one family (PMID: 10424815). Some of these individuals also carried a pathogenic variant in the MYBPC3 gene that could explain the observation of a more severely affected phenotype (PMID: 10424815). This variant has been identified in 2/282856 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000539828 SCV004848505 likely pathogenic Hypertrophic cardiomyopathy 2019-10-14 criteria provided, single submitter clinical testing The p.Glu483Lys variant in MYH7 has been reported in 5 individuals with HCM (Richard 1999, Berge 2014, Walsh 2017). One of these individuals also carried a nonsense variant in MYBPC3. Her affected son carried both variants and 4 additional affected family members carried only the p.Glu483Lys variant in MYH7. The proband and her son were reported to be more severely affected than family members carring either the MYH7 or MYBPC3 variant in isolation (Richard 1999). It has also been identified in 2/129164 of European chromosomes by gnomAD ( and reported in ClinVar (Variation ID# 14119). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. This variant lies in the head region of the protein and missense variants in this region are statistically more likely to be disease-associated (Walsh 2016). In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant HCM. ACMG/AMP Criteria applied: PM1, PM2, PS4_Supporting, PP1.
OMIM RCV000015176 SCV000035433 pathogenic Hypertrophic cardiomyopathy 1 1999-07-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.